The present invention provides methods for the preparation of gas-filled microbubbles, and methods of using for therapeutic and/or diagnostic applications. In particular, the methods of the invention allow for the preparation of gas-filled microbubbles having narrow size distributions and defined ultrasonic properties.
method of gene expression profiling to identify genomic signatures linked to survival specific for a disease and a kit that can be used for performing such a method. Also disclosed herein is the use of such a method in classifying the disease into subsets, predicting clinical outcome and survival of an individual, selecting treatment for an individual suffering from a disease, predicting post-relapse risk and survival of an individual, correlating molecular classification of a disease with genomic signature defining the risk group or a combination thereof.
A mouth guard including a top mouth piece for engaging the top teeth and a bottom mouth piece for engaging the bottom teeth. The mouth guard also includes a central section having one or more ports for receiving an endotracheal tube, oral gastric tube, and/or oral suction tube. In a first preferred embodiment, a top portion of the central section is attached to the top mouth piece, and a bottom portion of the central section is attached to the bottom mouth piece. In a second preferred embodiment, the entire central section is attached to the bottom mouth piece.
Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases
Novel alkylindoles that bind tightly to cannabinoid receptors and are neutral antagonists for the cannabinoid 1 receptor and agonists for the cannabinoid 2 receptor are provided. These compounds are useful for treating alcoholism and drug abuse and for treating obesity.
The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (−) methamphetamine, (−) amphetamine, or (−) MDMA.
Provided herein are compounds, comprising Formula (I) or Formula (II), and their pharmaceutically acceptable salts. Also provided are pharmaceutical compositions comprising a pharmaceutically acceptable excipient and at least one compound of Formula (I) and (II), singly or in combination with other pharmaceutically active ingredients, such as anti-inflammatory agents or anticancer agents.
Gene expression profiling based identification of CKS1B as a potential therapeutic target in multiple myeloma
The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma.
The present invention is drawn to methods of repairing lytic bone lesions and tumor growth in an individual. In this regard, the present invention discloses use of a Wnt ligand either alone or in combination with anti-Wnt signaling antagonist therapy.
The present invention encompasses classical cannabinoid metabolites and uses thereof.